Carmustine polifeprosan 20 wafer

Drug Profile

Carmustine polifeprosan 20 wafer

Alternative Names: BCNU; BIODEL carmustine; Carmustine BIODEL; Gliadel; Gliadel® Wafer; NPC-08; NSC-409962; WR-139021

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Massachusetts Institute of Technology
  • Developer Arbor Pharmaceuticals; Eisai Co Ltd; Nobelpharma; Orphan Australia
  • Class Antineoplastics; Nitrosourea compounds; Small molecules
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glioma

Most Recent Events

  • 02 Sep 2015 The Japanese MHLW lifts the all-case surveillance condition required for the approval of Gliadel® for the treatment of Glioma
  • 24 Apr 2015 Launched for Glioma in Mexico (Intracerebral)
  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top